Coherus Oncology (CHRS) Cash from Investing Activities Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | 20.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.49% |
| Dec 31, 2025 | 72.04% |
| Sep 30, 2025 | -427.89% |
| Jun 30, 2025 | 708.11% |
| Mar 31, 2025 | 21.11% |
| Dec 31, 2024 | -26.10% |
| Sep 30, 2024 | -69.72% |
| Jun 30, 2024 | 5.45% |
| Mar 31, 2024 | 39.42% |
| Dec 31, 2023 | -44.87% |
| Sep 30, 2023 | 45.51% |
| Jun 30, 2023 | 29.52% |
| Mar 31, 2023 | 134.20% |
| Dec 31, 2022 | -177.76% |
| Sep 30, 2022 | -16.50% |
| Jun 30, 2022 | -28.05% |
| Mar 31, 2022 | -32.82% |
| Dec 31, 2021 | 89.54% |
| Sep 30, 2021 | 7.67% |
| Jun 30, 2021 | 50.67% |